342 results on '"Garfall, A. L."'
Search Results
2. Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel
3. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
4. Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1
5. Teclistamab in Relapsed or Refractory Multiple Myeloma
6. High SOX2 expression is associated with poor survival in patients with newly diagnosed multiple myeloma
7. Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma
8. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines
9. Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy
10. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
11. Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells
12. Human IL-6 fosters long-term engraftment of patient derived disease-driving myeloma cells in immunodeficient mice
13. CAR T-Cell Immunotherapy in Minority Patients with Lymphoma
14. Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma
15. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
16. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
17. Options at the time of relapse after anti-BCMA therapy
18. Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies
19. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma
20. Understanding Infection Risk with Anti-BCMA Bispecific Antibodies
21. New Biological Therapies for Multiple Myeloma
22. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
23. RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation
24. New Biological Therapies for Multiple Myeloma.
25. Survival outcomes for patients with relapsed/refractory aggressive B cell lymphomas following receipt of high dose chemotherapy/autologous stem transplantation and/or chimeric antigen receptor-modified T cells
26. Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
27. Supplementary Figure from Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma
28. Supplementary Table from Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma
29. Supplementary Data from Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma
30. Data from Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
31. Data from Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma
32. Supplementary Tables and Figures from Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
33. sTable 1, sTable 2, sTable 3, sFigure 1, sFigure 2, sFigure 3, sFigure 4 from The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma
34. Long Term Neurologic Outcomes for Patients Receiving CAR-T Therapy for Non-Hodgkin’s Lymphoma Who Developed Severe Neurotoxicity
35. Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
36. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study
37. Progressive multifocal leukoencephalopathy in multiple myeloma
38. Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma
39. Phase 2 Study of Belantamab Mafodotin As Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission
40. MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody
41. Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed/Refractory Multiple Myeloma
42. Overcoming CD19-Negative Relapses in Patients with B-Cell Lymphomas Treated with Tisagenlecleucel
43. The NSG-hIL6 Mouse As a Novel Murine Patient Derived Xenograft Model of Plasma Cell Dyscrasias for Study of Disease Biology and Therapeutic Development
44. Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM)
45. MM-344 Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM)
46. MM-336 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
47. Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
48. Trispecific antibodies offer a third way forward for anticancer immunotherapy
49. Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma
50. Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.